

- **Name:** **Scott Kopetz**
 - **Current Position & Affiliation:** **Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center**
 - **Country:** **USA**
-

- **Educational Background:**

EDUCATION

Degree-Granting Education

Vanderbilt University, Nashville, TN, BE, Summa Cum Laude, 1997, Biomedical Engineering/ Electrical Engineering

Johns Hopkins School of Medicine, Baltimore, MD, MD, 2001, Medicine

University of Texas, Graduate School of Biomedical Sciences, Houston, TX, PhD, 2009, Patient Oriented Biological Research/ Cancer Biology

Postgraduate Training

Residency, Internal Medicine, Duke University Medical Center, Durham, NC, Diana McNeil, 7/2001-6/2004

Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Robert Wolff, 7/2004-6/2006

CREDENTIALS

Board Certification

Internal Medicine, 10/2004-10/2014

Medical Oncology, 10/2006-10/2028

Licensures

Active

Texas Medical Board, TX, L8776, 6/2004-11/2020

- **Professional Experience:**

Member, NCI Gastrointestinal Steering Committee, Bethesda, MD, 2014-2017

Senior Editor, Clinical Cancer Research, Bethesda, MD, 2014-present

NRG Vice Chair, Colon Cancer, NSABP/RTOG/GOG (NRG) Cooperative Group, Philadelphia, 2015-present

Member, ASCO TAPUR/Targeted Agent and Profiling Utilization Registry Board, Alexandria, VA, 12/2015-present

Member, ASCO Grant Steering Committee Executive Committee, Alexandria, VA, 2016-2018

Chair, NCI Colon Task Force, Bethesda, MD, 2017-present

Member, Scientific Advisory Board of the K.G. Jebsen Colorectal Cancer Research Centre, Oslo, Norway, 5/2017-present

US Representative, Pan-Asia

• **Professional Organizations:**

Operational Priority: Decisive Discoveries "Learning from the Patient" Focus Working Group, Member, 2017-present

Operational Priority: Decisive Discoveries "Key Knowledge Gaps in Biology" Focus Working Group, Member, 2017-present

EMD Serono / MD Anderson Alliance, Joint Steering Committee, Co-Leader, 2017-present

Guardant Health / MD Anderson Alliance, Joint Steering Committee, Member, 2017-present

Epidemiology Chair Search Committee, Member, 2017

Astellas/Joint Steering Committee, Member, 2018-present

Lilly Oncology/MD Anderson Alliance, Joint Steering Committee, Co-Leader, 2018-present

• **Main Scientific Publications:**

294. Advani SM, Shi Q, Overman MJ, Loree JM, Lam M, Morris V, Shureiqi I, Kee B, Dasari A, Vilar E, Sarshekeh AM, Lin HK, Manuel S, Hamilton S, Raghav K, Maru D, Kopetz S, Wang XS. Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. *Clin Colorectal Cancer* 19(1):48-56.e2, 3/2020. e-Pub 10/2019. PMID: 32008976.

295. McGrail DJ, Garnett J, Yin J, Dai H, Shih DJH, Lam TNA, Li Y, Sun C, Li Y, Schmandt R, Wu JY, Hu L, Liang Y, Peng G, Jonasch E, Menter D, Yates MS, Kopetz S, Lu KH, Broaddus R, Mills GB, Sahni N, Lin SY. Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. *Cancer Cell* 37(3):371-386.e12, 3/2020. e-Pub 2/2020. PMID: 32109374.

296. Hayes-Jordan AA, Sandler G, Malakorn S, Xiao LC, Kopetz S, Rodriguez-Bigas M. Colon Cancer in Patients Under 25 Years Old: A Different Disease? *J Am Coll Surg* 230(4):648-656, 4/2020. e-Pub 2/2020. PMID: 32092356.

297. Dragomir MP, Kopetz S, Ajani JA, Calin GA. Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility. *Gut* 69(4):748-763, 4/2020. e-Pub 2/2020. PMID: 32034004.

298. Ludford K, Cohen R, Svrcek M, Foo WC, Colle R, Parc Y, Thomas JV, Morris VK, Kopetz S, Chang GJ, Overman M, Andre T. Pathological tumor response following immune checkpoint blockade for deficient mismatch repair advanced colorectal cancer. *J Natl Cancer Inst.* e-Pub 4/2020. PMID: 32294214.